This is a free paper from China. It finds significant correlations between iron content and clinical symptoms of PD, even in Mini-Mental status. If 434 reduces iron content in MSA ( 201 study) in Substancia Nigra, putamen, etc it is likely or at least possible that it does the same in PD. This kind of research strongly supports the usage of ATH434 in PD, at least in severe cases of PD if 434 works in MSA, but today, it is only in my opinion.Association between deep gray matter iron deposition and clinical symptoms in Parkinson's disease: a quantitative susceptibility mapping study
AffiliationsPMCID: PMC11743366 DOI: 10.3389/fneur.2024.1442903
- PMID: 39835146
Abstract
Purpose: This study aimed to assess the association between motor and non-motor symptoms of Parkinson's disease (PD) and iron accumulation within the deep gray matter of the brain by Quantitative Susceptibility Mapping (QSM).
Methods: Fifty-six PD patients and twenty-nine healthy controls were recruited in this study. According to the Hoehn and Yahr (H-Y) stage score, PD patients were divided into early stage (H-Y ≤ 2) and advanced stage (H-Y > 2) groups. Specifically, the Regions of Interest (ROIs) encompassed the substantia nigra (SN), red nucleus (RN), caudate nucleus (CN), globus pallidus (GP) and putamen (PT). Meanwhile, various rating scales were used to assess the clinical symptoms of PD.
Results: Compared to healthy controls (HCs), PD patients showed a significant increase in magnetic susceptibility values (MSVs) within the SN and GP. Further comparisons indicated that the MSVs of the SN, PT, GP and CN are all higher in advanced stages than in early stages. Significant positive correlations were observed between the MSVs of the SN and scores on the UPDRS-III, HAMA, and HAMD (r = 0.310, p = 0.020; r = 0.273, p = 0.042; r = 0.342, p = 0.010, respectively). Likewise, the MSVs of the GP demonstrated notable correlations with HAMA and HAMD scores (r = 0.275, p = 0.040; r = 0.415, p = 0.001). Additionally, a significant correlation was found between the MSVs of the PT and HAMD scores (r = 0.360, p = 0.006). Furthermore, we identified a significant negative correlation between MMSE scores and the MSVs of both the PT and GP (r = -0.268, p = 0.046; r = -0.305, p = 0.022).
Conclusion: Our study revealed that QSM possesses the capability to serve as a biomarker for PD. Significant correlations were found between clinical features and the iron deposition in the nigrostriatal system.
- Forums
- ASX - By Stock
- ATH
- Grey matter iron / clinical symptoms in PD
ATH
alterity therapeutics limited
Add to My Watchlist
10.0%
!
1.1¢

Grey matter iron / clinical symptoms in PD
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $119.6M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.0¢ | $94.56K | 8.870M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
55 | 23455037 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 25358010 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
54 | 22788372 | 0.010 |
22 | 11716276 | 0.009 |
16 | 6529122 | 0.008 |
7 | 3172858 | 0.007 |
11 | 4129035 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 25358010 | 8 |
0.012 | 2612798 | 12 |
0.013 | 6301337 | 21 |
0.014 | 10343692 | 12 |
0.015 | 22177489 | 15 |
Last trade - 16.10pm 17/09/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |